With the debate swirling around the efficacy and safety of UV-C technology, an individual needs which generation the product is. Infection Control Today® continues its ongoing special reporting on UV-C technology.
Even though the germicidal effects of ultraviolet light were first discovered in 1877, currently in the health care industry, a debate of the efficacy of ultraviolet-C light (UV-C) technology continues. Also, with some investigators publishing studies showing it is safe and others not, the question comes down to which company’s technology works and what does not. Are the studies the companies are using their own, done by an independent research firm, or are the companies using competitors’ data? What generation of UV-C technology are the investigators using?
In the second of 2 segments of this exclusive Infection Control Today® (ICT®) interview with Gunner Lyslo, founder and CEO of Surfacide, continues the discussion on where the industry is going and what questions for health care facilities, schools, businesses, and others should ask when they are looking for UVC technology to keep their employees and visitors safe.
Although, UV-C has been proven to be effectual against SARS-CoV-2, some individuals still are hesitant to consider UV-C technology. Lyslo pushes back and says that second generation technology (like Surfacide) demonstrates that the technology is effective.
“It's an incredibly important technology [and] disinfection modality. And if used in an evidence-based way, with the proper indications for use, it will have a tremendous impact to the benefit of all those end users and all those individuals who are entering those spaces. [This is true] whether it would be a hospital, which hospitals are still first and foremost to [Surfacide], because that's where you're dealing with an immunocompromised patient population, as well as you're dealing with an environmental services team are frontline health care workers who have numerous workplace stresses.”
The first part of the interview with Lyslo is here.
Reflecting on the US Withdrawal from the World Health Organization
January 21st 2025An infection preventionist reels from the US exit from WHO, writing that it disrupts global health efforts, weakens infection control, and lacks research funding and support for low-income nations dependent on WHO for health care resources.
Infections Do Not Recognize International Borders: The Potential Impact of US Withdrawal From WHO
January 21st 2025The US withdrawal from WHO jeopardizes infection prevention, research funding, and global collaboration, disproportionately impacting low-income nations reliant on WHO support for equitable health care advancements.
Infection Intel:EvaClean Expands Global Reach With Microsplitting Partnership
January 20th 2025EvaClean partners with Microsplitting Ltd. to distribute its advanced disinfection systems and absorbents, revolutionizing infection prevention across health care, education, hospitality, and industrial sectors worldwide.